Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and Modulatory effect of statins

PLoS ONE

Volumn 3, Issue 9, 2008, Pages

  Zineh, Issam ^a   Beitelshees, Amber L ^a   Welder, Gregory J ^a   Hou, Wei ^b   Chegini, Nasser ^b   Wu, Jun ^c   Cresci, Sharon ^c   Province, Michael A ^c   Spertus, John A ^d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTIDINE; DNA; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GUANOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; CXCL5 PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; PEPTIDE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOGENOMICS; PROGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; SURVIVAL TIME; AGED; CHEMISTRY; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROSPECTIVE STUDY;

ENA;

ACUTE CORONARY SYNDROME; AGED; CHEMOKINE CXCL5; COHORT STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; NEUTROPHILS; PEPTIDES; PROGNOSIS; PROSPECTIVE STUDIES; PYRROLES;

EID: 52049120384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003117     Document Type: Article

References (43)

1. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
2. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
3. Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627-1652.
4. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
5. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, et al. (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50: 2117-2124.
6. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, et al. (1991) Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 174: 1355-1362.
7. Schmouder RL, Streiter RM, Walz A, Kunkel SL (1995) Epithelial-derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and in renal allograft rejection. Transplantation 59: 118-124.
8. Imaizumi T, Kumagai M, Hatakeyama M, Tamo W, Yamashita K, et al. (2003) Effect of 15-deoxy-delta 12,14-prostaglandin J2 on IL-1 beta-induced expression of epithelial neutrophil-activating protein-78 in human endothelial cells. Prostaglandins Leukot Essent Fatty Acids 69: 323-327.
9. Strieter RM, Kunkel SL, Burdick MD, Lincoln PM, Walz A (1992) The detection of a novel neutrophil-activating peptide (ENA-78) using a sensitive ELISA. Immunol Invest 21: 589-596.
10. Damas JK, Gullestad L, Ueland T, Solum NO, Simonsen S, et al. (2000) CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 45: 428-436.
11. Zaremba J, Skrobanski P, Losy J (2006) The level of chemokine CXCL5 in the cerebrospinal fluid is increased during the first 24 hours of ischaemic stroke and correlates with the size of early brain damage. Folia Morphol (Warsz) 65: 1-5.
12. Damas JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, et al. (2000) Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47: 778-787.
13. Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arant CB, et al. (2006) CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine 33: 258-263.
14. Schwartz GG, Olsson AG (2005) The case for intensive statin therapy after acute coronary syndromes. Am J Cardiol 96: 45F-53F.
15. Zineh I, Luo X, Welder GJ, Debella AE, Wessel TR, et al. (2006) Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 26: 333-340.
16. Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo, C, et al. (2007) Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 83: 1374-1380.
17. Cowled PA, Khanna A, Laws PE, Field JB, Varelias A, et al. (2007) Statins inhibit neutrophil infiltration in skeletal muscle reperfusion injury. J Surg Res 141: 267-276.
18. Guasti L, Marino F, Cosentino M, Cimpanelli M, Maio RC, et al. (2006) Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. J Hypertens 24: 2423-2430.
19. Marino F, Guasti L, Cosentino M, Ferrari M, Rasini E, et al. (2007) Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol 49: 299-305.
20. Sugano R, Matsuoka H, Haramaki N, Umei H, Murase E, et al. (2005) Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies. Arterioscler Thromb Vasc Biol 25: 1262-1267.
21. Smith C, Damas JK, Otterdal K, Oie E, Sandberg WJ, et al. (2006) Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol 48: 1591-1599.
22. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, et al. (2001) Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 1: 105-118.
23. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
24. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 285: 1711-1718.
25. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, et al. (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49: 1272-1278.
26. Brown JH, Del Re DP, Sussman MA (2006) The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98: 730-742.
27. Ota K, Suehiro, T, Arii K, Ikeda Y, Kumon Y, et al. (2005) Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 54: 142-150.
28. Aarons CB, Cohen PA, Gower A, Reed KL, Leeman SE, et al. (2007) Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg 245: 176-184.
29. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, et al. (2006) Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev 2: 93-102.
30. Furman G, Copin C, Kandoussi M, Davidson R, Moreau M, et al. (2004) Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 174: 93-98.
31. Lindholm MW, Nilsson J (2007) Simvastatin stimulates macrophage interleukin-1beta secretion through an isoprenylation-dependent mechanism. Vascul Pharmacol 46: 91-96.
32. Mandey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 54: 3690-3695.
33. Haller MJ, Pierce GL, Braith RW, Silverstein JH (2006) Serum superoxide dismutase activity and nitric oxide do not correlate with arterial stiffness in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 19: 267-269.
34. Zineh I, Beitelshees AL, Haller MJ (2007) NOS3 polymorphisms are associated with arterial stiffness in children with type 1 diabetes. Diabetes Care 30: 689-693.
35. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, et al. (2001) Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 87: 257-261.
36. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, et al. (2005) Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. Jama 294: 1526-1533.
37. Braunwald E (1989) Unstable angina. A classification. Circulation 80: 410-414.
38. Zineh I, Welder GJ, Langaee TY (2006) Development and cross-validation of sequencing-based assays for genotyping common polymorphisms of the CXCL5 gene. Clin Chim Acta 370: 72-75.
39. Kruk M, Przyluski J, Kalinczuk L, Pregowski J, Deptuch T, et al. (2008) Association of Non-Specific Inflammatory Activation With Early Mortality in Patients With ST-Elevation Acute Coronary Syndrome Treated With Primary Angioplasty. Circ J 72: 205-211.
40. Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L (2005) Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 95: 452-456.
41. Takeshita S, Isshiki T, Ochiai M, Ishikawa T, Nishiyama Y, et al. (1997) Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes. Atherosclerosis 135: 187-192.
42. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, et al. (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15: 1640-1649.
43. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.